Publications by authors named "E Imbalzano"
Background: Sodium-glucose co-transporter-2 inhibitors (SGLT2i) are recommended for reducing the renal and cardiovascular risk in patients with chronic kidney disease (CKD) based on the positive results reported by clinical trials. However, real-world data on the efficacy and the safety of these drugs in CKD population followed in nephrology setting are lacking.
Methods: We report the effects of dapagliflozin in CKD patients by using data collected during a learning program in which 105 nephrologists added dapagliflozin (10 mg/day) to consecutive patients referred to their renal clinics.
Reduction of hypokalaemia with finerenone: a drug or class-specific effect?
Eur Heart J Cardiovasc Pharmacother
January 2025
Article Synopsis
- Obstructive sleep apnoea (OSA) is prevalent among elderly patients with cardiovascular issues, yet it often goes unrecognized and untreated.
- The study enrolled 420 patients aged 65+ with paroxysmal atrial fibrillation and moderate to severe OSA to compare the effects of Continuous Positive Airway Pressure (CPAP) treatment against no treatment over an average of 22 months.
- Results showed that CPAP significantly reduced the risk of major cardiovascular events (MACE) and recurrence of atrial fibrillation in patients when combined with regular medical care.
Article Synopsis
- Physicians often don't follow heart failure treatment guidelines well, particularly when it comes to prescribed dosage levels.
- Non-cardiologists usually show even lower compliance with these guidelines, which can negatively affect patient outcomes like survival rates and quality of life.
- This document seeks to identify reasons for these issues and offers updated guidance for starting and increasing heart failure medication dosages, aimed at both cardiologists and general practitioners.
No risk factors have been identified for vaccine-induced immune thrombotic thrombocytopenia (VITT) so far. The aim of this study was to identify human leucocyte antigen (HLA) alleles potentially associated with VITT susceptibility. Specific HLA class II alleles were detected with significantly higher frequency in VITT patients compared with Italian controls: DPB1*17:01, DQA1*05:01, and DRB1*11:04.
View Article and Find Full Text PDF